FDA orders new warning on Ozempic, Wegovy, other GLP-1 drugs over rare eye condition
The U.S. Food and Drug Administration announced Monday that it is requiring new warnings on popular diabetes and weight loss drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, over a potential increased risk for a rare eye condition that can cause permanent vision loss. The condition, called nonarteritic anterior ischemic optic...
